[Dusseldorf, November 15, 2021]:
Everlife Holdings Pte. Ltd. (“Everlife”), a leading market access and medical device distributor in Asia, and Boditech Med Inc (“Boditech Med”), a leading manufacturer of Point-Of-Care Testing (“POCT”) products, met at Medica 2021 to sign agreements to introduce Boditech Med’s products in India and Malaysia. POCT products, which are diagnostic tests that can be administered by medical staff in the ward or clinic, are able to return results accurately yet faster than conventional lab testing, allowing clinicians to confirm diagnosis and begin treatment sooner. The global POCT market is predicted to exceed US$ 45 Billion by 2026, with Asia Pacific expected to grow at the fastest rate as demand for healthcare in the region increases and new and more technologically advanced products are introduced.
Everlife’s subsidiaries, CPC Diagnostics Pvt. Ltd. (“CPC”) and Chemopharm Sdn. Bhd. (“Chemopharm”), will have commercialization rights for Boditech Med’s EZ-POC and ichroma brands in India and Malaysia respectively. The products will undergo local registration before being commercially available, where the collaborating companies will work together to shape the POCT market in their respective territories, and to also identify new opportunities to collaborate.
Boditech Med was founded in 1998 initially as antibody manufacturer before entering the IVD space in 2000. Today, the company is recognized as one of the leading players in the POCT space, with more than 80 million tests run on their platform and customers in more than 120 countries. Boditech Med offers one of the most comprehensive portfolios of POCT test parameters, with some tests able to return results in as little as 3 minutes. The company has also developed proprietary sample collection technology, which allows tests to be run on very small amounts of whole blood. The fast turnaround and simple and convenient sample collection are critical particularly in the ICU and Emergency Care settings where patients face life-threatening situations.
Mr. Raman Gandotra, CEO of Everlife, said, “We are very excited to have the opportunity to collaborate with a world-class company like Boditech Med. These products have the potential to really make a significant difference to patient lives and enable better outcomes, and we are looking forward to bringing these to market soon.”
Everlife Group is one of Asia’s leading and most trusted market access and distribution platforms for medical devices and laboratory equipment and supplies. By combining our expertise in healthcare and Asia with a passionate and results-driven approach to business, we aim to improve health outcomes for patients and improve business performance for customers and principals. Everlife companies represent over 200 principals and a team of 800 employees that operate across 6 countries. Everlife is part of the Everstone Group and Cure Capital is a minority investor. To learn more, visit www.everlifeasia.com or visit us on LinkedIn.